Physician profile
Abdul S Shaikh
NPI 1619088358
$2,283.22
in general payments reported to CMS, 2019-2025
21 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $401 · 2021: $268 · 2022: $161 · 2023: $248 · 2024: $544 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $554.43 | 2019-2025 | Qelbree |
| Corcept Therapeutics | $299.80 | 2021-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.29 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $149.63 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $141.16 | 2019-2024 | Tepezza |
| Abbvie INC. | $137.21 | 2019-2023 | Qulipta, Ubrelvy, Botox |
| Cequr Corporation | $135.78 | 2024 | Cequr Simplicity |
| Insulet Corporation | $99.42 | 2025 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $96.37 | 2024 | Uzedy |
| Idorsia Pharmaceuticals US INC | $66.15 | 2022 | |
| Acclarent, INC | $64.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $57.06 | 2020 | |
| Novartis Pharmaceuticals Corporation | $28.34 | 2019-2020 | |
| Exact Sciences Corporation | $26.87 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $23.70 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $22.16 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $20.12 | 2025 | Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $19.56 | 2025 | Zepbound, Mounjaro |
| Grifols USA, LLC | $18.33 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.56 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.